Premium
A severe case of haemodynamic instability during anidulafungin administration
Author(s) -
Fink M.,
Zerlauth U.,
Kaulfersch C.,
Rab A.,
Alberer D.,
Preiss P.,
SternadKlobschauer K.,
Habernig E.,
Wandschneider W.,
Grimm G.
Publication year - 2013
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.12046
Subject(s) - anidulafungin , hemodynamics , medicine , administration (probate law) , anesthesia , cardiology , political science , law , antifungal , micafungin , dermatology , amphotericin b
Summary What is known and objective Anidulafugin is an echinocandin used for the treatment of candida infections in non‐neutropenic adults. Echinocandins show few drug–drug interactions and are usually well tolerated. We report a case of acute hypotension, bradycardia and haemodynamic instability with consecutive cardiopulmonary resuscitation during anidulafungin administration. Case summary A 41‐year‐old man ICU patient received anidulafungin for a suspected C andida glabrata infection. During the first administration of the drug, he developed acute haemodynamic instability with hypotension and bradycardia. The infusion was discontinued immediately and cardiopulmonary resuscitation was performed successfully. The patient regained haemodynamic stability. What is new and conclusion To the authors' knowledge, this is the first report of a life‐threatening adverse event due to haemodynamic instability during anidulafungin administration. Cardiac toxicity associated with echinocandins has been described. Further studies seem to be mandatory to investigate this potential risk.